CFM
EW icon

Catalyst Funds Management’s Edwards Lifesciences EW Stock Holding History

Catalyst Funds Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Buy
3,900
+665
+21% +$55.7K 0.02% 472
2026
Q1 		$259K Buy
+3,235
New +$267K 0.04% 397
2024
Q3 		– Sell
-600
Closed -$55.4K – 1390
2024
Q2 		$55.4K Buy
+600
New +$53.1K 0.01% 396

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Catalyst Funds Management's EW Position: Q2 2026 in Review

Catalyst Funds Management increased its Edwards Lifesciences (EW) stake by 21% in Q2 2026, buying an estimated $55.7K and bringing the position to 3,900 shares worth $353K. The position accounts for 0.02% of the portfolio, ranked #472.

Catalyst Funds Management first reported a position in EW in Q2 2024 and has held it in 3 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Catalyst Funds Management held 3,900 shares of Edwards Lifesciences worth $353K as of Q2 2026.
  • Catalyst Funds Management bought 665 Edwards Lifesciences shares in Q2 2026, an estimated $55.7K.
  • Edwards Lifesciences made up 0.02% of Catalyst Funds Management's portfolio in Q2 2026, its #472 holding.
  • Catalyst Funds Management first reported a position in Edwards Lifesciences in Q2 2024 and has held it in 3 quarters since.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.